DNA 자이레이스 서브유닛 B(EC 5.99.1.3) : 파이프라인 리뷰

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

DNA 자이레이스 서브유닛 B(EC 5.99.1.3)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업이나 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

• 조사 범위

DNA 자이레이스 서브유닛 B(EC 5.99.1.3) 개요

치료제 개발

• 개발중인 제품 : 개발 단계별
• 개발중인 제품 : 치료 영역별
• 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

• 초기 단계 제품
• 개발 단계가 불명확한 제품

기업에서 개발중인 제품

치료제 평가

• 단독치료 제품(Monotherapy Products)/병용 제품(Combination Products)별
• 작용기전별
• 투여 경로별
• 분자 종류별

치료제 개발에 참여하고 있는 기업

• Abgentis Limited
• AstraZeneca Plc
• Daiichi-Sankyo
• Merck & Co., Inc.

약제 개요

주요 뉴스 및 프레스 릴리스

부록

도표

List of Tables

• Number of Products under Development by Stage of Development, H2 2019
• Number of Products under Development by Therapy Areas, H2 2019
• Number of Products under Development by Indication, H2 2019
• Number of Products under Development by Companies, H2 2019
• Products under Development by Companies, H2 2019
• Number of Products by Stage and Mechanism of Actions, H2 2019
• Number of Products by Stage and Route of Administration, H2 2019
• Number of Products by Stage and Molecule Type, H2 2019
• Pipeline by Abgentis Ltd, H2 2019
• Pipeline by AstraZeneca Plc, H2 2019
• Pipeline by Daiichi Sankyo Co Ltd, H2 2019
• Pipeline by Spero Therapeutics Inc, H2 2019
• Dormant Projects, H2 2019

List of Figures

• Number of Products under Development by Stage of Development, H2 2019
• Number of Products under Development by Top 10 Indications, H2 2019
• Number of Products by Stage and Mechanism of Actions, H2 2019
• Number of Products by Routes of Administration, H2 2019
• Number of Products by Stage and Routes of Administration, H2 2019
• Number of Products by Stage and Molecule Type, H2 2019

Summary

DNA Gyrase Subunit B (EC 5.99.1.3) pipeline Target constitutes close to 6 molecules. The latest report DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2019, outlays comprehensive information on the DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

DNA Gyrase Subunit B (EC 5.99.1.3) - DNA gyrase is an essential bacterial enzyme that catalyzes the ATP-dependent negative super-coiling of double-stranded closed-circular DNA. DNA gyrase has two subunits. One of the subunit is B which introduces negative supercoils. Subunit B is selectively inactivated by antibiotics such as coumermycin A1 and novobiocin. Inhibition of either subunit blocks super twisting activity. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 2, 3 and 1 respectively. Report covers products from therapy areas Infectious Disease which include indications Acinetobacter Infections, Clostridium difficile Infections (Clostridium difficile Associated Disease), Escherichia coli Infections, Bacterial Infections, Klebsiella pneumoniae Infections, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Mycobacterium Infections, Pseudomonas aeruginosa Infections and Tuberculosis.

Furthermore, this report also reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

• The report provides a snapshot of the global therapeutic landscape for DNA Gyrase Subunit B (EC 5.99.1.3)
• The report reviews DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics and enlists all their major and minor projects
• The report assesses DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to DNA Gyrase Subunit B (EC 5.99.1.3) targeted therapeutics

Reasons to buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for DNA Gyrase Subunit B (EC 5.99.1.3)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding DNA Gyrase Subunit B (EC 5.99.1.3) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

• Introduction
• Global Markets Direct Report Coverage
• DNA Gyrase Subunit B (EC 5.99.1.3) - Overview
• DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Development
• Products under Development by Stage of Development
• Products under Development by Therapy Area
• Products under Development by Indication
• Products under Development by Companies
• DNA Gyrase Subunit B (EC 5.99.1.3) - Therapeutics Assessment
• Assessment by Mechanism of Action
• Assessment by Route of Administration
• Assessment by Molecule Type
• DNA Gyrase Subunit B (EC 5.99.1.3) - Companies Involved in Therapeutics Development
• Abgentis Ltd
• AstraZeneca Plc
• Daiichi Sankyo Co Ltd
• Spero Therapeutics Inc
• DNA Gyrase Subunit B (EC 5.99.1.3) - Drug Profiles
• DS-11960558 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• DS-2969 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• GYR-12 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• Small Molecules to Inhibit DNA Gyrase B and DNA Topoisomerase IV for Gram Negative Bacterial Infections - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• SPR-720 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• VXC-100 - Drug Profile
• Product Description
• Mechanism Of Action
• R&D Progress
• DNA Gyrase Subunit B (EC 5.99.1.3) - Dormant Products
• DNA Gyrase Subunit B (EC 5.99.1.3) - Product Development Milestones
• Featured News & Press Releases
• Dec 04, 2019: Spero reports preliminary findings from phase 1 clinical trial of SPR720 and announces plans to advance program into proof-of-concept clinical trial in patients with NTM Pulmonary Disease
• Nov 26, 2019: Spero Therapeutics provides new update on SPR720
• Jun 17, 2019: Spero Therapeutics to present data for all pipeline programs including SPR-720 at the ASM Microbe 2019 Conference
• Feb 26, 2019: Spero Therapeutics receives QIDP Designation from the U.S. FDA for the Development of SPR720
• Jan 30, 2019: Spero starts Phase I trial of SPR720 for NTM infections
• Nov 05, 2018: Spero Therapeutics announces positive results from SPR720 IND-Enabling studies and plans to initiate a phase 1 Trial
• Jun 05, 2018: Spero Therapeutics to Present Data On SPR720 at ASM Microbe 2018
• May 30, 2017: Spero Therapeutics Presents New Data on SPR720 at ASM Microbe 2017
• May 04, 2017: Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis
• Appendix
• Methodology
• Coverage
• Secondary Research
• Primary Research
• Expert Panel Validation
• Contact Us
• Disclaimer